《中華老年多器官疾病雜志》投稿須知

《中華老年多器官疾病雜志》是由中國(guó)人民解放軍總醫(yī)院主管、中國(guó)人民解放軍總醫(yī)院老年心血管病研究所主辦、國(guó)內(nèi)外公開(kāi)發(fā)行的醫(yī)學(xué)學(xué)術(shù)期刊，月刊，大16開(kāi)本。本刊屬中國(guó)科技論文統(tǒng)計(jì)源期刊(中國(guó)科技核心期刊)，被國(guó)內(nèi)各大檢索系統(tǒng)和美國(guó)《化學(xué)文摘》等國(guó)際知名檢索系統(tǒng)收錄。

1 雜志簡(jiǎn)介

《中華老年多器官疾病雜志》主要交流老年心血管疾病、尤其是老年心血管疾病合并其他疾病、老年兩個(gè)以上器官疾病以及其他老年多發(fā)疾病的預(yù)防、診斷、治療經(jīng)驗(yàn)與教訓(xùn)，探討其發(fā)病機(jī)制和有效診治措施；重點(diǎn)報(bào)道我國(guó)在上述疾病研究中具有創(chuàng)新意義的臨床、基礎(chǔ)和預(yù)防方面的最新成果和經(jīng)驗(yàn)；以從事老年心臟病學(xué)和(或)老年醫(yī)學(xué)及其相關(guān)疾病專業(yè)的醫(yī)療、科研及教學(xué)人員為主要讀者對(duì)象。

主要欄目有專家述評(píng)、專題論壇、臨床研究、基礎(chǔ)研究、臨床藥學(xué)、病例報(bào)告、新技術(shù)與新方法、臨床病理討論、綜述、學(xué)術(shù)動(dòng)態(tài)、專家科普講座、醫(yī)學(xué)論文寫(xiě)作等。

歡迎參與“一帶一路”建設(shè)的國(guó)家和地區(qū)的學(xué)者向本刊投稿和訂閱本刊，與我們共享老年醫(yī)學(xué)發(fā)展成果和經(jīng)驗(yàn)。如來(lái)稿為英文，請(qǐng)于英文摘要后附相應(yīng)中文摘要。如作者不能提供中文，本刊可代為免費(fèi)翻譯。

2 撰 稿

2.1 總則

文稿應(yīng)具有實(shí)用性、科學(xué)性、創(chuàng)新性。文稿應(yīng)表達(dá)準(zhǔn)確、文字簡(jiǎn)練、重點(diǎn)突出、結(jié)論可信。論著、綜述、講座類文章不宜超過(guò)5 000字；經(jīng)驗(yàn)交流、病例報(bào)告不宜超過(guò)1 500字；專家述評(píng)、專題筆談、學(xué)術(shù)動(dòng)態(tài)、醫(yī)學(xué)論文寫(xiě)作類文稿視具體情況而定。

2.2 文題

簡(jiǎn)明醒目，能確切反映全文主要內(nèi)容。盡量避免使用符號(hào)、簡(jiǎn)稱、縮寫(xiě)及商品名等。各類文稿均須附英文題名。中英文標(biāo)題內(nèi)容應(yīng)基本一致。中文題名一般不宜超過(guò)20個(gè)漢字，英文題名不宜超過(guò)10個(gè)實(shí)詞。

2.3 作者和單位

作者姓名列于文題下。作者應(yīng)具備下列條件：①參與選題和設(shè)計(jì)，并是工作的主要實(shí)施組織者；②論文的起草、修改者或提出關(guān)鍵性觀點(diǎn)及主要內(nèi)容的修改者；③能按編輯部的正確意見(jiàn)進(jìn)行修改、并進(jìn)行學(xué)術(shù)答辯者。姓名之間用逗號(hào)隔開(kāi)。注明所有作者的單位全稱(具體到科室)、城市及郵政編碼。第一署名單位應(yīng)是進(jìn)行研究工作和提供研究條件的機(jī)構(gòu)單位。若作者隸屬單位與第一署名單位不一致，可在首頁(yè)腳注第一作者現(xiàn)工作單位。列出第一作者和通信作者姓名、學(xué)位、職稱、職務(wù)、電話和手機(jī)號(hào)碼、傳真號(hào)、E-mail信箱和通過(guò)郵局寄收郵件的詳細(xì)地址與郵政編碼。通信作者姓名右上角加“*”。

2.4 摘要

專家述評(píng)、專題筆談、論著、綜述、講座等欄目的文章，均須附中英文摘要。論著稿件要求寫(xiě)成四段結(jié)構(gòu)式摘要，內(nèi)容包括目的、方法、結(jié)果(應(yīng)有主要數(shù)據(jù))和結(jié)論。述評(píng)、專家論壇、綜述等采用指示性摘要。摘要內(nèi)容應(yīng)包含與論文同等量的主要信息，簡(jiǎn)潔、明了，高度概括全文內(nèi)容，能獨(dú)立成文。摘要中不引用文獻(xiàn)，不進(jìn)行評(píng)論和解釋。論著稿件摘要字?jǐn)?shù)不宜少于250字，述評(píng)、綜述等不宜少于150字，能獨(dú)立成文。英文摘要與中文摘要文意基本一致，應(yīng)比中文摘要更詳細(xì)。

2.5 關(guān)鍵詞

在中英文摘要下面標(biāo)引3～8個(gè)關(guān)鍵詞。盡量采用全國(guó)科學(xué)名詞審定委員會(huì)公布的醫(yī)學(xué)名詞術(shù)語(yǔ)，英文采用新版《醫(yī)學(xué)索引》(Index Medicus，IM)中的醫(yī)學(xué)主題詞表(MeSH)中的術(shù)語(yǔ)，如果醫(yī)學(xué)主題詞表中的術(shù)語(yǔ)不適合新出現(xiàn)的專業(yè)術(shù)語(yǔ)，則可直接采用新術(shù)語(yǔ)。關(guān)鍵詞間用“ ; ”分隔。

2.6 中圖分類號(hào)

請(qǐng)根據(jù)論文內(nèi)容的學(xué)科分類從《中國(guó)圖書(shū)館分類法》中查得。

2.7 基金項(xiàng)目

若論文為基金資助課題，請(qǐng)?jiān)谑醉?yè)腳注基金項(xiàng)目名稱和編號(hào)。須中英文對(duì)照，英文內(nèi)容置于英文關(guān)鍵詞后，如This work was supported by…。

2.8 正文

論著文稿一般按引言、對(duì)象(材料)與方法、結(jié)果、討論的格式撰寫(xiě)。

2.8.1 引言 說(shuō)明該研究領(lǐng)域的現(xiàn)狀、存在的問(wèn)題和本研究的目的。文字必須言簡(jiǎn)意賅，不能與正文中的其他內(nèi)容重復(fù)。合理引用最新或最經(jīng)典的參考文獻(xiàn)，有效闡明論文的重要價(jià)值。

2.8.2 對(duì)象(材料)與方法 清楚地描述觀察或?qū)嶒?yàn)對(duì)象的選擇(患者或?qū)嶒?yàn)動(dòng)物，包括對(duì)照)，說(shuō)明研究對(duì)象的年齡、性別和其他重要特征。介紹研究方法、儀器(在括號(hào)中注明廠家名稱和地址)和實(shí)驗(yàn)步驟，應(yīng)提供足夠的細(xì)節(jié)以便他人重復(fù)而得到類似的結(jié)果(提供已建立方法的參考文獻(xiàn)；提供已發(fā)表但尚不被熟知的方法的參考文獻(xiàn)，并做簡(jiǎn)要描述；詳述新的或進(jìn)行重大改良的方法，說(shuō)明采用以上方法的理由，并評(píng)估其局限性)。準(zhǔn)確說(shuō)明所用藥物和化學(xué)試劑的通用名稱、使用劑量和給藥途徑。臨床研究必須遵循《赫爾辛基宣言》的原則，對(duì)任何涉及人體的研究均應(yīng)注明得到受試者知情同意，并獲得倫理委員會(huì)的批準(zhǔn)；任何動(dòng)物實(shí)驗(yàn)研究均應(yīng)聲明遵循《實(shí)驗(yàn)動(dòng)物保護(hù)條例》。臨床試驗(yàn)應(yīng)報(bào)告所有主要研究要素，包括受試對(duì)象的納入和排除標(biāo)準(zhǔn)、隨機(jī)化方法、干預(yù)措施和盲法措施等。

2.8.3 統(tǒng)計(jì)學(xué) 詳細(xì)描述統(tǒng)計(jì)學(xué)方法(如成組設(shè)計(jì)資料的t檢驗(yàn)、兩因素析因設(shè)計(jì)資料的方差分析、多個(gè)均數(shù)之間兩兩比較的q檢驗(yàn)等)，以使具有專業(yè)知識(shí)的讀者能夠通過(guò)原始數(shù)據(jù)檢驗(yàn)所報(bào)告的結(jié)果。若可能，應(yīng)定量描述結(jié)果，并給出測(cè)量誤差的適當(dāng)指標(biāo)或不確定性(如可信區(qū)間)。

2.8.4 結(jié)果 綜合使用文字描述、表格、統(tǒng)計(jì)圖或典型照片對(duì)論文主題或引言中提到的問(wèn)題依次分段敘述，可列小標(biāo)題。文字描述和圖表表達(dá)的內(nèi)容避免重復(fù)，同時(shí)應(yīng)注意圖表表達(dá)符合統(tǒng)計(jì)學(xué)要求。仔細(xì)核對(duì)數(shù)據(jù)，結(jié)果中病例數(shù)應(yīng)與入選時(shí)研究對(duì)象的例數(shù)相同，如有不一致，應(yīng)描述剔除或失訪的病例數(shù)和原因。不應(yīng)簡(jiǎn)單羅列研究過(guò)程中所得到的各種原始材料和數(shù)據(jù)，需描述經(jīng)過(guò)統(tǒng)計(jì)學(xué)分析的結(jié)果。如研究數(shù)據(jù)差異無(wú)統(tǒng)計(jì)學(xué)意義，應(yīng)指明是否有臨床意義。

2.8.5 討論 著重強(qiáng)調(diào)本研究的主要發(fā)現(xiàn)和結(jié)果的重要性，與引言相呼應(yīng)。對(duì)得出的結(jié)果進(jìn)行分析，而非重復(fù)引言或結(jié)果部分的數(shù)據(jù)或其他資料。列出本研究的不足之處，包括設(shè)計(jì)中可能存在的偏差。在已完成的工作基礎(chǔ)上，提出新的研究課題或思路，指出今后進(jìn)一步研究的方向。

2.9 層次結(jié)構(gòu)

各層次一律采用阿拉伯?dāng)?shù)字分級(jí)編號(hào)，均左頂格書(shū)寫(xiě)，后空一格寫(xiě)標(biāo)題文字；二級(jí)以上層次序號(hào)的數(shù)字間用下圓點(diǎn)相隔，末位數(shù)字后不加圓點(diǎn)。例如：“1”、“1.1”、“1.1.1”。

2.10 表和圖

按表和圖在正文中出現(xiàn)的先后順序用從“1”開(kāi)始的阿拉伯?dāng)?shù)字連續(xù)編號(hào)。應(yīng)少而精，有“自明性”，表和圖不要重復(fù)同一數(shù)據(jù)。表和圖的標(biāo)題用中英文雙語(yǔ)表示，內(nèi)容及注釋用英文表示，英文縮寫(xiě)在注釋中注明，可提供圖表內(nèi)容的中文對(duì)照。

2.10.1 表格 采用“三線表”。合理安排表格縱、橫標(biāo)目，應(yīng)正確、易懂、符合統(tǒng)計(jì)學(xué)要求。量的名稱或符號(hào)與單位符號(hào)采用“量(單位)”的形式，如time(min)。表格中注釋用的角碼符號(hào)采用以下形式，其順序?yàn)?、#、△、▲、☆、★、**、##、△△等，在表注中依先縱后橫的順序依次標(biāo)出。

2.10.2 圖 要求冠有圖題和相應(yīng)的說(shuō)明，說(shuō)明性文字置于圖下方注釋中。組合圖中的不同子圖，用A，B，C注明。坐標(biāo)圖高寬比例適當(dāng)，標(biāo)目簡(jiǎn)明，且必須標(biāo)注量的名稱或符號(hào)和單位符號(hào)，如Age(years)。照片圖要清晰，對(duì)比度好。黑白圖和彩色圖的分辨率不能<600 dpi。圖上的字母、數(shù)字和符號(hào)應(yīng)該清晰、均勻且大小適中(7～12磅)，以便出版時(shí)易于辨認(rèn)。圖片為T(mén)IF或JPEG文件。病理照片應(yīng)標(biāo)明放大倍數(shù)與染色方法，所需顯示的部分置于照片中央或用箭頭標(biāo)示。對(duì)可辨認(rèn)的患者照片，應(yīng)征得患者的書(shū)面同意，并遮蓋其能被辨認(rèn)出系何人的部分。如圖、表引自他刊，應(yīng)注明出處，并附版權(quán)所有者同意使用該圖的書(shū)面材料。

2.11 名詞術(shù)語(yǔ)

以全國(guó)自然科學(xué)名詞審定委員會(huì)審定公布的《醫(yī)學(xué)名詞》(科學(xué)出版社出版)為準(zhǔn)，未審定公布的名詞則參照《英漢醫(yī)學(xué)詞匯》(人民衛(wèi)生出版社出版)。中外名詞術(shù)語(yǔ)應(yīng)使用全稱，縮寫(xiě)首次出現(xiàn)時(shí)加括號(hào)注明。藥物名稱采用最新版《中華人民共和國(guó)藥典》和《中國(guó)藥品通用名稱》中的名稱，應(yīng)使用通用名，可標(biāo)注商品名，并注明英文名。

2.12 計(jì)量單位

采用法定計(jì)量單位。具體參照中華醫(yī)學(xué)會(huì)雜志社編寫(xiě)的《法定計(jì)量單位在醫(yī)學(xué)上的應(yīng)用》(2004年，第3版，人民軍醫(yī)出版社)一書(shū)。在一個(gè)組合單位符號(hào)的表示中只可以采用1條斜線的形式，如mg/kg，mmol/L等表示，但若有2個(gè)以上單位時(shí)，應(yīng)采用負(fù)數(shù)冪的形式表示，如“ng/(kg·min)”，不能用“ng/kg/min”表示，也不能寫(xiě)為“ng/kg·min-1”。量和單位之間空1/4格。百分?jǐn)?shù)起止前后均應(yīng)加百分符號(hào)，如40%～60%。面積用長(zhǎng)×寬表示，應(yīng)寫(xiě)成2 cm×3 cm，不應(yīng)寫(xiě)成2×3 cm2；體積用長(zhǎng)×寬×高表示，應(yīng)寫(xiě)成2 cm×3 cm×4 cm，不應(yīng)寫(xiě)成2×3×4 cm3。血壓的計(jì)量單位使用mmHg，首次使用時(shí)應(yīng)注明mmHg或cmH2O與kPa的換算系數(shù)(1 mmHg=0.133 kPa，1 cmH2O=0.098 kPa)。避免使用不規(guī)范單位符號(hào)，如“rpm”應(yīng)寫(xiě)為“轉(zhuǎn)/min”，濃度單位“M”應(yīng)寫(xiě)成“mol/L”，避免濃度當(dāng)量“N”單位符號(hào)。

2.13 數(shù)字

凡是可以使用阿拉伯?dāng)?shù)字且很得體的地方，均應(yīng)使用阿拉伯?dāng)?shù)字。一系列數(shù)值的計(jì)量單位一致時(shí)，只在最末一個(gè)數(shù)值后標(biāo)明單位即可，如5、10、15、20 mol/L。單位相同的量值范圍，前一個(gè)量值單位可以省略，如3～6 kg。其他如60%～85%，4×109～7×109或(4～7)×109，(25±1)℃。以百分?jǐn)?shù)表示的均數(shù)±標(biāo)準(zhǔn)差寫(xiě)法如(40.5±0.6)%。完整數(shù)字不移行。分?jǐn)?shù)則橫寫(xiě)，如2/6，4/7。數(shù)值的修約應(yīng)為“4舍6入5看后，5后有數(shù)進(jìn)上去，5后為0看左數(shù)，左數(shù)奇進(jìn)偶不進(jìn)”。

2.14 統(tǒng)計(jì)學(xué)符號(hào)

統(tǒng)計(jì)學(xué)符號(hào)均用斜體，如P(概率)、(樣本的算術(shù)平均數(shù))、s(標(biāo)準(zhǔn)差)、S(標(biāo)準(zhǔn)誤)、t(t檢驗(yàn))、F(F檢驗(yàn))、χ2(卡方檢驗(yàn))、r(相關(guān)系數(shù))、v(自由度)等。

2.15 縮略語(yǔ)

在摘要及正文中首次出現(xiàn)縮略語(yǔ)時(shí)應(yīng)給出其中英文全稱?？s略語(yǔ)應(yīng)盡量少用，1篇文章內(nèi)一般不宜超過(guò)5個(gè)，不超過(guò)4個(gè)漢字的名詞一般不使用縮略語(yǔ)，以免影響文章的可讀性。

2.16 參考文獻(xiàn)

應(yīng)選用親自閱讀的近5年內(nèi)公開(kāi)發(fā)表的文獻(xiàn)。作者必須對(duì)照原文核查每一條參考文獻(xiàn)。采用順序編碼制，按文內(nèi)引用先后編序，其序號(hào)標(biāo)注于右上角方括號(hào)內(nèi)。同一處引用多篇文獻(xiàn)時(shí)，須將各篇文獻(xiàn)的序號(hào)在方括號(hào)內(nèi)全部列出，各序號(hào)間用“，”隔開(kāi)，如遇連續(xù)序號(hào)，可標(biāo)注起止序號(hào)，連續(xù)兩篇文獻(xiàn)的序號(hào)，用“，”隔開(kāi)，如[1,2]。文末按引文順序列出，務(wù)必注意文獻(xiàn)的準(zhǔn)確性。作者列出第1～3名，超過(guò)3名時(shí)，后加“等”或“etal.”。題名后標(biāo)注文獻(xiàn)類型(期刊，J；普通圖書(shū)，M；會(huì)議論文集，C；匯編，G；報(bào)紙, N；學(xué)位論文，D；報(bào)告，R；標(biāo)準(zhǔn)，S；專利，P；數(shù)據(jù)庫(kù)，DB；計(jì)算機(jī)程序，CP；電子公告，EB)和載體類型(磁帶，MT；磁盤(pán)，DK；光盤(pán)，CD；聯(lián)機(jī)網(wǎng)絡(luò)，OL)標(biāo)識(shí)代碼。外文期刊名稱用縮寫(xiě)，采用美國(guó)國(guó)立圖書(shū)館Medline/PubMed數(shù)據(jù)庫(kù)的刊名縮寫(xiě)形式。中文期刊用全名。中文文獻(xiàn)采用中英文雙語(yǔ)著錄。參考文獻(xiàn)如有“數(shù)字對(duì)象唯一標(biāo)識(shí)符(DOI)”編碼，應(yīng)著錄，列于末尾。

各類文獻(xiàn)的著錄格式如下。

〔期刊〕

著錄格式：[序號(hào)]作者. 文題[J]. 刊名, 年, 卷(期): 起頁(yè)-止頁(yè). DOI.

示例：

[1] Williamson JD, Supiano MA, Applegate WB,etal. Intensivevsstandard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial[J]. JAMA, 2016, 315(24): 2673-2682. DOI: 10.1001/jama.2016.7050.

[2] 謝朝云, 蒙桂鸞, 熊蕓, 等. 慢性阻塞性肺疾病急性發(fā)作患者復(fù)種菌感染相關(guān)因素分析[J]. 中華老年多器官疾病雜志, 2019, 18(7): 485-488. DOI: 10.11915/j.issn.1671-5403.2019.07.103.

Xie ZY, Meng GL, Xiong Y,etal. Relevant factors of multiple bacterial infections in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Chin J Mult Organ Dis Elderly, 2019, 18(7): 485-488. DOI: 10.11915/j.issn.1671-5403.2019.07.103.

〔專著〕

著錄格式：[序號(hào)]著者. 書(shū)名[M]. 版次. 出版地: 出版者, 出版年: 起頁(yè)-止頁(yè).

示例：

[3] 陸再英, 鐘南山. 內(nèi)科學(xué)[M]. 第7版. 北京: 人民衛(wèi)生出版社, 2008: 18-19.

Lu ZY, Zhong NS. Internal Medicine[M].7th ed. Beijing: People′s Medical Publishing House, 2008:18-19.

〔專著中的析出文獻(xiàn)〕

著錄格式：[序號(hào)]析出文獻(xiàn)著者. 析出文獻(xiàn)篇名[A]//專著編者. 書(shū)名[M]. 版次. 出版地: 出版者, 出版年: 起頁(yè)-止頁(yè).

示例：

[4] Curtis DH,Drew JW.Infection after liver transplantation[A]//Ronald WB, Goran KK. Transplantation of the Liver[M]. 2nd ed. Philadelphia: Saunders, 2005: 978-980.

〔電子文獻(xiàn)〕

著錄格式：主要責(zé)任者. 題名: 其他題名信息[文獻(xiàn)類型標(biāo)志/文獻(xiàn)載體標(biāo)志]. 出版地: 出版者, 出版年(更新或修改日期)[引用日期]. 獲取和訪問(wèn)路徑示例：

[5] World Association of Medical Editors. Policy statement on authorship[EB/OL]. [2010-10-16]. http://www. wame.org/resources/policies#authorship.

2.17 志謝

置于正文之后、參考文獻(xiàn)之前。文字力求簡(jiǎn)練，評(píng)價(jià)得當(dāng)，并應(yīng)征得被志謝者本人同意。

3 投 稿

3.1 投稿規(guī)則

請(qǐng)作者投稿前仔細(xì)閱讀"投稿須知"。一旦投稿，即被自動(dòng)認(rèn)為全部作者已閱讀并理解和接受"投稿須知"的內(nèi)容和要求。投稿同時(shí)須提交加蓋公章的單位介紹信，證明稿件內(nèi)容屬實(shí)、無(wú)一稿多投、不涉及保密、署名無(wú)爭(zhēng)議等。一旦發(fā)現(xiàn)稿件內(nèi)容虛假不實(shí)、一稿多投或重復(fù)發(fā)表，將追究其法律責(zé)任，作出賠償。投稿時(shí)可附投稿信，介紹稿件及研究工作相關(guān)信息。

3.2 稿件處理

所有稿件均經(jīng)2～3位同行專家審閱；論著類稿件經(jīng)同行專家審閱后，須上定稿會(huì)討論并由主編或副主編最終決定是否錄用。編輯部有權(quán)對(duì)文稿進(jìn)行必要的文字性刪減。如不同意刪改請(qǐng)事先申明。編輯部會(huì)在3個(gè)月內(nèi)通知作者稿件處理意見(jiàn)。未收到通知者，請(qǐng)及時(shí)向編輯部查詢。在此之前，請(qǐng)勿另投他刊。

3.3 出版費(fèi)用

本刊免收版面費(fèi)，并酌致稿酬(已含網(wǎng)絡(luò)版、光盤(pán)版稿酬)。如需購(gòu)買(mǎi)單行本者，請(qǐng)預(yù)先說(shuō)明。

3.4 綠色通道

本刊為重大研究成果開(kāi)辟“綠色通道”。凡要求以“綠色通道”發(fā)表的論文，作者應(yīng)提供關(guān)于論文創(chuàng)新性的書(shū)面說(shuō)明和查新報(bào)告。經(jīng)主編審核同意后，最快于2個(gè)月內(nèi)即可發(fā)表。

3.5 投稿方式/地址

請(qǐng)通過(guò)網(wǎng)上投稿 (http://mode301.ijournals.com.cn)，投稿文件格式為word文檔。

《中華老年多器官疾病雜志》編輯部

地址： 100853 北京市復(fù)興路28號(hào)

電話： 010-66936756

電子郵箱： zhlndqg@mode301.cn

InstructionsforAuthors

TheChineseJournalofMultipleOrganDiseasesintheElderly(ZhonghuaLaonianDuoqiguanJibingZazhi) (ISSN 1671-5403) is launched in 2002 and published monthly by the Institute of Geriatric Cardiology(IGC), Chinese PLA General Hospital in Beijing, China.

1AbouttheJournal

ChineseJournalofMultipleOrganDiseasesintheElderly(theJournal) is a peer-reviewed medical journal for all physicians, researchers, and health-care workers from geriatric specialties. The journal contributes to the scientific advancement of geriatrics by disseminating high quality research with potential to advance knowledge for geriatrics. The journal welcomes manuscripts that are relevant to the care of older persons with cardiovascular diseases, especially those with concomitant diseases of other major organs orsystems, such as the lungs, kidneys, liver, central nervous system, gastrointestinal tract or endocrinology,etc. The submissions related to the geriatrics, including basic, clinical and preventive medicine, are all acceptable.

Manuscriptsfromthecountriesalong“theBeltandRoad”arealsowelcome.ForEnglishmanuscripts,itisnecessarytoattachaChineseabstractaswell.Iftheauthorscann′tprovide,wewillofferafreetranslationservice.

2PublicationProcess

2.1 Manuscript submission

Manuscripts are submitted online at http://mode301.ijournals.com.cn. Upon the receipt of the manuscript, the authors will receive a confirmation of the submission. When inquiring about a manuscript, please refer to the assigned manuscript number.

2.2 Review

All submitted manuscripts, either commissioned or unsolicited, are reviewed initially by an editor. If judged suitable for consideration, they are sent to two external referees for peer review (single-blind review). Authors are encouraged to indicate the names of 2-3 potential referees (providing their full postal and electronic addresses and contact numbers) they believe are qualified to review the paper. Authors may also request disqualification of up to two referees with potential conflict of interest. But the editor will make the final choice.

If reviewers express widely different opinions or disagree on the decision to accept, the article may be sent to a third reviewer. All manuscripts are discussed at a meeting of the editor-in-chief and standing members of the editorial board. This committee makes the final decision to accept or reject the manuscript.

Any study containing quantitative data and statistical inference should be reviewed by a consultant with formal statistical training and experience.

2.3 Revision

Manuscripts are accepted for publication on the basis of scientific merit, significance, and suitability for publication devoted to clinical and laboratory studies of geriatrics. Authors should revise their manuscript to comply with the requirement on the reviewers′ comments and the style oftheJournal. If a revision of an original article is not received within 2 months from the last decision letter of an editor,theJournalwill assume that the authors have withdrawn the manuscript from further consideration. If the revision is not satisfactory to the editors and referees, the author may be asked to make a second revision. On publication, each report indicates the date that the original manuscript was received at the editorial office and the date that the manuscript was finally accepted. If a manuscript is not accepted, the author will receive a decision letter with the reviewers′ comments.

2.4 Proofreading

Manuscripts accepted for publication are copyedited and returned to the author for approval. Authors are responsible for all statements published in their work, including any changes made by the copy editor. The publisher is not responsible for any errors not marked by the author on the proof. Authors are required to proofread all edited manuscripts carefully. The proof must be returned to the Editorial Office within 7 days of receipt.

2.5 Copyright assignment

Copyright ownership of published manuscript is to be transferred to the publisher, IGC of Chinese PLA General Hospital, in a written statement, which must accompany all manuscript submissions and must be signed by all authors.

3ManuscriptPreparation

Manuscripts must conform totheJournal“Instructions for Authors” and/or “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” by the International Committee of Medical Journal Editors(ICMJE) (www.icmje.org). Recent issues of the Journal should be consulted for example.

3.1 Title page

The title page should contain: 1) a concise and descriptive title of the paper; 2) the full names and institutional affiliations of all authors; and 3) the name, address, telephone number, fax number, and E-mail address of the corresponding author.

3.2 Authorship

Each author should have participated sufficiently in the preparation of the manuscript, and have reviewed and approved the manuscript as submitted to take public responsibility for it. This would include substantial participation in some or all of the following aspects of the work relating to the manuscript: 1) involvement in the conception, hypothesis delineation, and design of the study; 2) acquisition of the data or the analysis and interpretation of such information; and 3) writing the article or substantial involvement in its revision prior to submission.

3.3 Abstract

Abstract of original research articles should consist of about 250 words and be structured in 4 parts: 1) Objective; 2) Methods; 3) Results; and 4) Conclusion. Full papers submitted to other sections (e.g., Editorials, Reviews, Clinicopathological Conference, Education and Training,etc.) require a simple narrative abstract of 250 words or less summarizing the content of the paper. An abstract is not required for the type of case report. The abstract should be self-explanatory, without reference to the text. Abbreviations may be included, provided they are defined in the abstracts as well as the main text.

3.4 Key words

Three to six words or short phrases should be provided as key words. We recommend terms from the Medical Subject Headings (MeSH) in PubMed. If suitable MeSH terms are not yet available for recently introduced terms, present terms may be used.

3.5 Sources of Funding

All sources of funding must be disclosed under English Abstract as “This work was supported by ……”, with grant number also given in brackets.

3.6 Main Text

The text for original research articles should be organized into the following sections: Introduction, Materials and Methods (including material or subject/population, statistical analysis,etc.), Results, and Discussion.

Introduction

Include both a brief review of literatures data that are strictly related to the object of the paper, and a short statement on the aims of the study. Give only strictly pertinent references and do not include data or conclusions from the work being reported.

Methods

Describe your selection of the observational or experimental subjects (patients or laboratory animals, including controls) clearly. Identify the age, sex, and other important characteristics of the subjects. Describe in sufficient detail to allow workers to duplicate the study. Previously reported procedures may be cited, but newly adopted modifications should be specified in detail. Statistical methods must be described and the program used for data analysis should be stated.

Results

Describe the major findings of the study clearly and concisely with the help of appropriate illustrative material. Do not repeat in the text all the data in the tables or illustrations.

Discussion

Summarize the major findings. Compare the reported findings with previous work. Propose their interpretation, and indicate their implications and limitations. Suggest future work. Produce a succinct conclusion. Conclusions should be linked to the goals of the study. Statements which are not completely supported by the data should be avoided.

3.7 Tables

Number all tables with Arabic numbers consecutively in order of appearance. Each table must have a concise heading and should be completely informative in itself without reference to the text. Symbols for units should be used only in column headings. Every column must have a description or heading. Do not use internal horizontal or vertical lines. Statistical measures of variations should be identified. All abbreviations must be defined in footnotes. For footnotes, use the following symbols in this sequence: *,#,△,▲,☆,★,**,##,△△,etc.

3.8 Figures

Figures must be referenced sequentially in the text. Multipart figures should be organized as single composites, with each panel labeled (e.g., A, B, C,etc.). We recommend saving figures as Joint Photographic Experts Group (JPEG) files, or Tagged Image Format (TIF) files with a resolution of 600 dots per inch (dpi) or better. Figures should be in black and white. Color photographs will occasionally be published intheJournalif use of color is vital to making the point. Figure legends should contain enough information for the reader to understand the illustration without referring to the text, but should be concise and should not repeat information already stated in the text.

Indicate the internal scale and identify the method of staining and magnification of photomicrographs. Do not publish any identifying information showing the likeness to the patient unless the information is essential for scientific purposes and the patient gives written informed consent for publication. The photograph or image of the patient must not be recognizable by the patient′s friends or family if it is to be acceptable. If a figure has been published, acknowledge the original source and provide written permission from the copyright holder to reproduce the material.

3.9 References

Number all references in the sequence in which they first appear in the text and use the style indicated in the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals.” Check the accuracy of all reference citations. Abbreviate the title of the journal according to the style used in the Index Medicus/Pubmed/MEDLINE. Cite only the names of the first three authors followed by “etal.” Include both the first and last pages of all references. Include only references that are accessible to all readers. Cite Chinese-language references in English-Chinese bilingual expression.

3.10 Acknowledgments

The correspondence author must affirm that he or she has listed everyone who contributed significantly to the work and has obtained written consent from all contributors who are not authors and are named in the Acknowledgment section. The Acknowledgment section may briefly include assistance from:1)contributors that do not warrant authorship; 2)technical help; 3) material support; and 4) financial support as a grant.

4Conflict-of-InterestStatement

Before a manuscript can be reviewed, all authors must sign a ICMJE Conflict of Interest form (http://www.icmje.org/conflicts-of-interest) declaring any possible financial, professional, or personal conflicts of interest that could conceivably bias the conduct, reporting, or interpretation of the research.

5StatementofInformedConsent

For reports concerning experiments on humans, authors must include at the beginning of the methods section a statement that all patients (or parents or guardians of those not able to provide informed consent) provided written, informed consent before the beginning of the study. All patients have a right to privacy that should not be violated. Identifying information, including but not limited to patients′ names, initials, hospital numbers, or images showing the likeness to the patient, should not be published in written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and the patient gives written informed consent for publication.

6StatementofHumanandAnimalRights

Human experiments should be performed only in accordance with the ethical standards provided by the responsible committee of the institution and in accordance with the World Medical Association Declaration of Helsinki (revised in 2013, http://www.wma.net/e/policy/b3.htm). Laboratory research involving animals must comply with guidelines for animal care and use. The experimental protocol must be approved by the Institutional Animal Care and Use Committee.

Address: Editorial Office,ChineseJournalofMultipleOrganDiseasesintheElderly, 28 Fuxing Road, Haidian District, Beijing 100853, China

Tel/Fax: 86-10-66936756

E-mail: zhlndgq@mode301.cn

http://mode301.ijournals.com.cn